SCHEMBL792497

SCHEMBL792497

COCc1cc([N+](=O)[O-])ccc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.56
TDP1 Q9NUW8 3/20 0.56
TSHR P16473 2/20 0.56
CYP3A4 P08684 4/20 0.51
CYP19A1 P11511 1/20 0.51
PDE2A O00408 1/20 0.47
PDE5A O76074 1/20 0.47
ALOX15 P16050 1/20 0.47
NFKB1 P19838 1/20 0.47
APEX1 P27695 1/20 0.47
PDE4A P27815 1/20 0.47
BLM P54132 1/20 0.47
PDE1B Q01064 1/20 0.47
PMP22 Q01453 1/20 0.47
PDE4B Q07343 1/20 0.47
PDE4D Q08499 1/20 0.47
PDE7A Q13946 1/20 0.47
PDE1C Q14123 1/20 0.47
PDE7B Q9NP56 1/20 0.47
HTT P42858 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28476778 0.88 ALDH1A1 (0.58) ALDH1A1TDP1TSHRCYP3A4CYP19A1
SCHEMBL13751494 0.87 ALDH1A1 (0.53) ALDH1A1TDP1TSHRCYP3A4CYP19A1
SCHEMBL792454 0.83 ALDH1A1 (0.53) ALDH1A1TDP1TSHRCYP3A4CYP19A1
SCHEMBL863443 0.83 HTT (0.57) ALDH1A1TDP1TSHRCYP3A4ALOX15
SCHEMBL11317000 0.83 HTT (0.49) ALDH1A1TDP1TSHRCYP3A4HTT
SCHEMBL5035784 0.82 CYP19A1 (0.54) ALDH1A1TDP1TSHRCYP3A4CYP19A1
SCHEMBL14768876 0.82 ALDH1A1 (0.64) ALDH1A1TDP1TSHRCYP3A4CYP19A1
SCHEMBL10175659 0.82 ALDH1A1 (0.64) ALDH1A1TDP1TSHRCYP3A4CYP19A1
SCHEMBL863466 0.81 GPR35 (0.51) ALDH1A1TDP1TSHRALOX15MAPT
SCHEMBL791991 0.81 HTT (0.44) ALDH1A1TDP1TSHRCYP3A4CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012044758-A1 METHODS OF SYNTHESIZING 2-METHOXYMETHYL-1,4-BENZENEDIAMINE THE PROCTER & GAMBLE COMPANY (US) 2012-04-05 WO disclosed
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-20120020920-A1 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-01-26 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed
US-20090036444-A1 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2009-02-05 US disclosed
US-7285551-B2 Fused-ring compounds and use thereof as drugs JAPAN TOBACCO INC. (JP) 2007-10-23 US disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 US disclosed
US-20070032497-A1 Fused-ring compounds and use thereof as drugs JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-4395577-A OF AMIDOMETHYL NITROBENZENE WITH PHOSPHORUS OXYCHLORIDE AMERICAN CYANAMID COMPANY (US) 1983-07-26 US disclosed
US-4297127-A PREEMERGENCE HERBICIDES AMERICAN CYANAMID COMPANY (US) 1981-10-27 US disclosed
US-4251264-A 4-CYANO SUBSTITUTED AMERICAN CYANAMID COMPANY (US) 1981-02-17 US disclosed
US-4165231-A 2,6-Dinitroaniline herbicides AMERICAN CYANAMID COMPANY (US) 1979-08-21 US disclosed
US-4124639-A N-alkoxyalkyl-2,6-dinitroaniline herbicides AMERICA CYANAMID COMPANY (US) 1978-11-07 US disclosed
US-4101582-A 2,6-Dinitroaniline herbicides AMERICAN CYANAMID COMPANY (US) 1978-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor POLI, TERT, ZC3HAV1 ALDH1A1 750/4885TDP1 3276/4885TSHR 4089/4885
US-20090036444-A1 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor GTF3C5, ZC3HAV1, POLI ALDH1A1 596/4885TDP1 3889/4885TSHR 4648/4885
US-20120020920-A1 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR GTF3C5, ZC3HAV1, POLI ALDH1A1 596/4885TDP1 3889/4885TSHR 4648/4885
US-20070032497-A1 Fused-ring compounds and use thereof as drugs HAVCR2, ZC3HAV1, HLA-C ALDH1A1 679/4885TDP1 3973/4885TSHR 4824/4885
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 ALDH1A1 750/4885TDP1 3276/4885TSHR 4089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.